18 months after it opened an investigation into Teva to see if it illegally blocked generic versions of its big-selling multiple sclerosis drug Copaxone, the European Commission has said it
In a dramatic change in fortunes, Novartis has won a major victory in its bid to defend oral multiple sclerosis therapy Gilenya from early generic competition in the US.
Amgen’s famously voracious legal team is living up to its reputation once again, this time with a surprise challenge on the patents surrounding Alexion’s rare diseases blockbuster, Soliris.